Genentech buys Regor's CDK inhibitors in $850m deal [Yahoo! Finance]
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: Yahoo! Finance
Pharmaceuticals' portfolio of breast cancer cyclin-dependent kinase (CDK) inhibitors in an $850m deal. The deal, anticipated to close in Q4 2024, was unveiled by Genentech's parent company Roche at its pharma day in London. The pharmaceutical giant also shared that it is focusing on three major therapeutic areas – one being oncology. Regor will continue to oversee its two ongoing Phase I trials of the CDK4/2 inhibitor RGT-419B until their completion. At that point, Genentech will take over the global clinical development, manufacturing, and commercialisation of the candidate. The deal also includes preclinical candidate RGT-587, which is a “Phase I ready” CDK4 inhibitor, intended to treat brain metastases. One of Regor's Phase Ia trials (NCT05304962) is investigating RGT-419B in 12 patients with HR+/HER2-negative advanced breast cancer who had previously undergone CDK4 treatment. Data showed that RGT-419B, administered as a monotherapy, achieved a 28.6% partial response rate and
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline [Seeking Alpha]Seeking Alpha
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery [Yahoo! Finance]Yahoo! Finance
- AI in Healthcare Market to Grow by USD 20.34 Billion (2024-2028), Driven by Healthcare Digitization, AI-Powered Report Highlights Market Transformation - TechnavioPR Newswire
- Recursion and Exscientia Shareholders Approve the Proposed Combination [Yahoo! Finance]Yahoo! Finance
- Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™PR Newswire
EXAI
Earnings
- 8/15/24 - Miss
EXAI
Sec Filings
- 11/20/24 - Form S-8
- 11/20/24 - Form S-8
- 11/20/24 - Form 6-K
- EXAI's page on the SEC website